New pill shows promise against tough lung cancer mutation
NCT ID NCT05466149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill called furmonertinib in about 100 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already tried chemotherapy. The goal is to see if the drug shrinks tumors and how safe it is. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jilin Province Cancer Hospital
Changchun, Jilin, 130000, China